Table 2 Primary published clinical... | American Society of Hematology

Table 2

Primary published clinical studies of childhood acute promyelocytic leukemia treated with ATO or ATRA plus CT

Study, year	No. of patients	Age, y	Induction	HCR (%)	Postremission therapy	Duration of postremission therapy	Estimated 5-year OS, %	Estimated 5-year EFS, %
George et al,²² 2004	11	≤ 15	ATO	91	ATO	8 mo	91	81
Present study, 2009	19	≤ 15	ATO	89	ATO	3 y	84	73
de Botton et al,³ 2004	31	≤ 18	ATRA + daunorubicin-cytarabine	97	CT and/or ATRA, BMT (n = 2)*	2 y, 2 mo	90	71
Testi et al,⁴ 2005	107	≤ 18	ATRA + idarubicin	96	CT and/or ATRA, BMT (n = 3)*	2 y, 3 mo	89	81
Ortega et al,² 2005	66	≤ 18	ATRA + idarubicin	92	CT + ATRA	2 y, 3 mo	87	77

Study, year	No. of patients	Age, y	Induction	HCR (%)	Postremission therapy	Duration of postremission therapy	Estimated 5-year OS, %	Estimated 5-year EFS, %
George et al,²² 2004	11	≤ 15	ATO	91	ATO	8 mo	91	81
Present study, 2009	19	≤ 15	ATO	89	ATO	3 y	84	73
de Botton et al,³ 2004	31	≤ 18	ATRA + daunorubicin-cytarabine	97	CT and/or ATRA, BMT (n = 2)*	2 y, 2 mo	90	71
Testi et al,⁴ 2005	107	≤ 18	ATRA + idarubicin	96	CT and/or ATRA, BMT (n = 3)*	2 y, 3 mo	89	81
Ortega et al,² 2005	66	≤ 18	ATRA + idarubicin	92	CT + ATRA	2 y, 3 mo	87	77

ATO indicates arsenic trioxide; ATRA, all-trans retinoic acid; CT, chemotherapy; BMT, bone marrow transplantation; EFS, event-free survival; HCR, complete hematologic remission; and OS, overall survival.

Denotes the number of patients who had a BMT in first remission.

View Large

This Feature Is Available To Subscribers Only